AUS
NZ
UK
CA
USA
IND
Highlights
- Prothena develops treatments targeting neurodegenerative diseases.
- PADOVA study explored prasinezumab for early Parkinson’s disease treatment.
- Results highlight key findings in motor progression delay.
Prothena (NASDAQ:PRTA) operates in the biotechnology sector, focusing on therapies for complex neurodegenerative conditions. Collaborating with Roche, the company aims to address Parkinson’s disease, a progressive neurological disorder that affects motor function. A prominent program under this partnership is prasinezumab, an experimental monoclonal antibody targeting alpha-synuclein, a protein linked to Parkinson’s disease.
Details of the PADOVA Study
The Phase IIb PADOVA trial evaluated the efficacy and safety of prasinezumab in early-stage Parkinson’s disease. Conducted over 18 or more months, the study included 586 participants. While the primary goal of delaying motor progression was not achieved, prasinezumab demonstrated certain clinical benefits, particularly in a subgroup receiving levodopa, a common Parkinson’s medication.
The overall motor progression delay was measured with a hazard ratio (HR) of 0.84. The levodopa-treated subgroup showed a stronger outcome, recording an HR of 0.79 and achieving statistical significance with a p-value of 0.0431.
Additional Findings
Covariate-adjusted analyses provided deeper insights into prasinezumab’s impact. For the primary endpoint, nominally significant improvements were observed, reflected by an HR of 0.81 and a p-value of 0.0334. Among participants in the levodopa subgroup, further improvement was noted with an HR of 0.76 and a p-value of 0.0175.
Safety Profile and Next Steps
Prasinezumab was well-tolerated throughout the trial, with no new safety concerns reported. Both the Phase II PASADENA and Phase IIb PADOVA open-label extension studies will continue, enabling researchers to gather more comprehensive data. Roche has announced plans to collaborate with health authorities to evaluate the future of prasinezumab’s development.
Prothena's work with Roche highlights their commitment to developing innovative approaches for addressing complex neurological conditions. While the PADOVA trial provided mixed results, it contributes valuable knowledge to ongoing research in Parkinson’s disease therapies.
